Phenol and glycerin in allergy extracts

Phenol appears in named allergenic-extract labels as a preservative. Preservation helps limit microbial growth under the product’s specified conditions; it is not a guarantee of sterility after mishandling, protection against all contamination or proof that a bottle remains usable after its assigned date.

Glycerin (also called glycerol) can form part of the liquid vehicle and help stabilize allergenic proteins. AAAAI’s SCIT preparation guidance also describes preservative effects in appropriate formulations. Its contribution depends on the final concentration, allergens, other diluents, container and storage history. “Glycerinated” is not a universal storage instruction.

Phenol and glycerin are not mutually exclusive. The named Allermed mite extract below contains both. Conversely, an ingredient list for one stock extract does not prove what another stock, diluent or final patient-specific mixture contains. “Preservative-free” and “phenol-free” are not interchangeable claims.

Weight/volume (w/v) expresses a mass in a volume of solution. Volume/volume (v/v) expresses a liquid volume relative to the final solution volume. A percentage without its basis can be ambiguous. In the named Allermed example, the phenol ingredient table’s 0.004 g per mL supports the 0.4% w/v interpretation; the glycerol description explicitly says 50% by volume. Do not transfer that unit interpretation to a different label that omits the basis.

An allergen extract’s source-material weight/volume ratio, an ingredient percentage, and potency units such as AU/mL or BAU/mL describe different properties. A ratio or vial color is not a phenol/glycerin concentration. Ask the pharmacist which quantity the label means rather than using one number to infer another.

A concentration alone is not the amount a person is exposed to. Exposure also depends on the administered volume, frequency, route and formulation. Those are matters for the pharmacist and prescribing clinician; this guide supplies no exposure calculation, dose threshold or self-management rule.

A manufacturer’s stock extract may be combined with other extracts and a diluent to prepare an individual prescription. The stock and added diluent can each contribute ingredients. Final concentrations therefore depend on the complete formulation; a stock label’s percentage is not automatically the percentage in the dispensed vial or oral-drop bottle.

An aqueous preparation is not necessarily phenol-free, and a glycerinated preparation is not necessarily phenol-free. Nor does using a diluent without phenol prove the final preparation has no phenol if the stock extracts contribute it. Request the final ingredient list and concentrations from the dispensing pharmacy, not an inference from one component.

The pharmacist must determine compatible ingredients, appropriate preparation conditions, labeling, storage and the beyond-use date. Patients should not dilute, combine, replace a diluent, remove a preservative or recalculate concentrations from this article. These actions can change allergen strength, stability and microbial protection.

The labels cited here describe skin-testing and/or injection products. Their stated ingredients and precautions are evidence about those named products and uses. They are not FDA approval of every oral mixture prepared from them. Likewise, evidence for an FDA-approved SLIT tablet is not automatically evidence for each custom liquid formulation, allergen combination or excipient exposure.

The presence of phenol does not, on its own, establish that a labeled product is unsuitable. The fact that an ingredient appears in a licensed product also does not guarantee that every concentration, route or final mixture is harmless. Assess the actual prescription, patient factors and exposure rather than treating an ingredient name as either a danger verdict or a safety seal.

Local irritation can have more than one explanation. The ALK therapeutic label notes injection-site discomfort with its glycerinated extracts; that is not a measured rate of oral irritation or a diagnosis of any patient’s symptoms. This resource cannot determine whether a reaction is caused by the allergen, phenol, glycerin or another ingredient. Persistent or concerning symptoms need the prescriber/pharmacist; breathing difficulty, throat swelling or faintness require urgent medical help and the prescribed emergency plan.

AAAAI’s preparation chapter is SCIT-focused guidance, not a toxicology trial of every compounded SLIT formula. Some cited labels describe gaps in long-term animal or reproductive data. Those limits should be acknowledged, not filled with claims of proven universal harmlessness or allegations of harm at an unspecified exposure. Individualized professional assessment remains necessary.

Glycerin can help preserve extract potency, but temperature, dilution, allergen compatibility, other stabilizers and the container still matter. Proteolytic enzymes in some extracts can affect other allergens in a mixture. A component’s stabilizing role is not a blanket shelf-life, potency or room-temperature guarantee.

The named ALK and Allermed labels require refrigerated storage for the products they cover and warn against freezing. That fact illustrates why the ingredient name alone cannot authorize unrefrigerated storage. It is not an instruction to impose those manufacturer stock conditions on every compounded oral bottle without checking its own label.

Follow the final dispensing label and assigned beyond-use date. If instructions are unclear or a temperature excursion occurred, ask the pharmacy for an assessment of the exact preparation. Do not borrow another provider’s storage windows or extend a date because the bottle contains glycerin.

USP <795> covers nonsterile preparations and USP <797> covers sterile preparations, including applicable allergenic-extract prescription-set requirements. Their scopes are different. Neither public chapter summary certifies a pharmacy or provides this bottle’s validated stability; the pharmacist must consult the current chapter and applicable rules.

FDA’s biologics guidance separately explains that 503A/503B drug-compounding exemptions do not apply to licensed biological products, and its allergenic-extract prescription-set policy is specifically for SCIT. Neither a pharmacy’s “503A” marketing description nor USP chapter scope establishes FDA approval or a legal exemption for oral allergen-biologic mixtures.